Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats

Neuropharmacology

Volumn 82, Issue , 2014, Pages 59-68

  Pałucha Poniewiera, Agnieszka ^a   Szewczyk, Bernadeta ^a   Pilc, Andrzej ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

AMN082; Antidepressant; mGlu receptors; MTEP; mTOR

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMN 082; GLUTAMATE RECEPTOR 1; MAMMALIAN TARGET OF RAPAMYCIN; METABOTROPIC RECEPTOR AGONIST; MITOGEN ACTIVATED PROTEIN KINASE; POSTSYNAPTIC DENSITY PROTEIN 95; SYNAPSIN I; UNCLASSIFIED DRUG; 2,3-DIOXO-6-NITRO-7-SULFAMOYLBENZO(F)QUINOXALINE; 3-((2-METHYL-1,3-THIAZOL-4-YL)ETHYNYL)PYRIDINE; AMINO ACID RECEPTOR BLOCKING AGENT; AMINO ACID RECEPTOR STIMULATING AGENT; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; BENZHYDRYL DERIVATIVE; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 1; GRM5 PROTEIN, RAT; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 7; MTOR PROTEIN, RAT; MULTIPROTEIN COMPLEX; N,N'-DIBENZHYDRYLETHANE-1,2-DIAMINE DIHYDROCHLORIDE; PYRIDINE DERIVATIVE; QUINOXALINE DERIVATIVE; RAPAMYCIN; SYNAPSIN; TARGET OF RAPAMYCIN KINASE; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FORCED SWIM TEST; IMMOBILITY; LOCOMOTION; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DEPRESSION; DRUG EFFECTS; METABOLISM; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZHYDRYL COMPOUNDS; DEPRESSION; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MULTIPROTEIN COMPLEXES; NEUROPSYCHOLOGICAL TESTS; PREFRONTAL CORTEX; PYRIDINES; QUINOXALINES; RATS, SPRAGUE-DAWLEY; RECEPTOR, METABOTROPIC GLUTAMATE 5; RECEPTORS, AMPA; RECEPTORS, METABOTROPIC GLUTAMATE; SIGNAL TRANSDUCTION; SIROLIMUS; SWIMMING; SYNAPSINS; THIAZOLES; TOR SERINE-THREONINE KINASES;

EID: 84897994660     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.03.001     Document Type: Article

References (33)

1. M. Aan Het Rot, C.A. Zarate Jr., D.S. Charney, and S.J. Mathew Ketamine for depression: where do we go from here? Biol. Psychiatry 72 2012 537 547
2. I.V. Belozertseva, T. Kos, P. Popik, W. Danysz, and A.Y. Bespalov Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests Eur. Neuropsychopharmacol. 17 2007 172 179 (Pubitemid 44779190)
3. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, D.S. Charney, and J.A. Krystal Antidepressant effects of ketamine in depressed patients Biol. Psychiatry 47 2000 351 354 (Pubitemid 30109248)
4. P.T. Bhaskar, and N. Hay The two TORCs and Akt Dev. Cell 12 2007 487 502 (Pubitemid 46523652)
5. S.R. Bradley, J.M. Uslaner, R.B. Flick, A. Lee, K.M. Groover, and P.H. Hutson The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling Pharmacol. Biochem. Behav. 101 2012 35 40
6. S. Chaki, R. Yoshikawa, S. Hirota, T. Shimazaki, M. Maeda, N. Kawashima, T. Yoshimizu, A. Yasuhara, K. Sakagami, S. Okuyama, S. Nakanishi, and A. Nakazato MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity Neuropharmacology 46 2004 457 467 (Pubitemid 38224431)
7. J.A. Clements, W.S. Nimmo, and I.S. Grant Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans J. Pharm. Sci. 71 1982 539 542 (Pubitemid 12063731)
8. H. Cline Synaptogenesis: a balancing act between excitation and inhibition Curr. Biol. 15 2005 203 205
9. P.J. Conn, and J.P. Pin Pharmacology and functions of metabotropic glutamate receptors Annu. Rev. Pharmacol. Toxicol. 37 1997 205 237 (Pubitemid 27238875)
10. P.B. Crino mTOR: a pathogenic signaling pathway in developmental brain malformations Trends Mol. Med. 17 2011 734 742
11. N. Diazgranados, L. Ibrahim, N.E. Brutsche, A. Newberg, P. Kronstein, S. Khalife, W.A. Kammerer, Z. Quezado, D.A. Luckenbaugh, G. Salvadore, R. Machado-Vieira, H.K. Manji, and C.A. Zarate A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression Arch. Gen. Psychiatry 67 2010 793 802
12. R.S. Duman, N. Li, R.J. Liu, V. Duric, and G. Aghajanian Signaling pathways underlying the rapid antidepressant actions of ketamine Neuropharmacology 62 2012 35 41
13. 2/3 blockade Int. J. Neuropsychopharmacol. 15 2012 429 434
14. A. Fekadu, S.C. Wooderson, K. Markopoulo, C. Donaldson, A. Papadopoulos, and A.J. Cleare What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies J. Affect. Disord. 116 2009 4 11
15. Z.A. Hughes, S.J. Neal, D.L. Smith, S.J. Sukoff Rizzo, C.M. Pulicicchio, S. Lotarski, S. Lu, J.M. Dwyer, J. Brennan, M. Olsen, C.N. Bender, E. Kouranova, T.H. Andree, J.E. Harrison, G.T. Whiteside, D. Springer, S.V. O'Neil, S.K. Leonard, L.E. Schechter, J. Dunlop, S. Rosenzweig-Lipson, and R.H. Ring Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression Neuropharmacology 66 2013 202 214
16. L. Ibrahim, N. Diazgranados, D.A. Luckenbaugh, R. Machado-Vieira, J. Baumann, A.G. Mallinger, and C.A. Zarate Jr. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 1155 1159
17. M. Iijima, K. Fukumoto, and S. Chaki Acute and sustained effects of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test Behav. Brain Res. 235 2012 287 292
18. J. Karasawa, T. Shimazaki, N. Kawashima, and S. Chaki AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist Brain Res. 1042 2005 92 98
19. H. Koike, M. Iijima, and S. Chaki Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists Neuropharmacology 61 2011 1419 1423
20. N. Li, B. Lee, R.J. Liu, M. Banasr, J.M. Dwyer, M. Iwata, X.Y. Li, G. Aghajanian, and R.S. Duman mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 2010 959 964
21. S. Maeng, C.A. Zarate Jr., J. Du, R.J. Schloesser, J. McCammon, G. Chen, and H.K. Manji Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors Biol. Psychiatry 63 2008 349 352 (Pubitemid 351146651)
22. A. Pałucha, P. Brański, B. Szewczyk, J.M. Wierońska, K. Kłak, and A. Pilc Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist Pharmacol. Biochem. Behav. 81 2005 901 906 (Pubitemid 41187826)
23. A. Pałucha, K. Kłak, P. Brański, H. van der Putten, P.J. Flor, and A. Pilc Activation of the mGlu7 receptor elicits antidepressant-like effects in mice Psychopharmacology 194 2007 555 562 (Pubitemid 47492987)
24. A. Pałucha-Poniewiera, P. Brański, T. Lenda, and A. Pilc The antidepressant-like action of metabotropic glutamate 7 receptor agonist N,N′-bis(diphenylmethyl)-1,2-ethanediamine (AMN082) is serotonin-dependent J. Pharmacol. Exp. Ther. 334 2010 1066 1074
25. A. Pałucha-Poniewiera, and A. Pilc A selective mGlu7 receptor antagonist MMPIP reversed antidepressant-like effects of AMN082 in rats Behav. Brain Res. 238 2013 109 112
26. A. Pałucha-Poniewiera, J.M. Wierońska, P. Brański, K. Stachowicz, S. Chaki, and A. Pilc On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039 Psychopharmacology 212 2010 523 535
27. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 1986 Academic Sydney
28. G. Pignataro, D. Capone, G. Polichetti, A. Vinciguerra, A. Gentile, G. Di Renzo, and L. Annunziato Neuroprotective, immunosuppressant and antineoplastic properties of mTOR inhibitors: current and emerging therapeutic options Curr. Opin. Pharmacol. 11 2011 378 394
29. A. Pilc, A. Kłodzińska, P. Brański, G. Nowak, A. Pałucha, B. Szewczyk, E. Tatarczyńska, E. Chojnacka-Wójcik, and J.M. Wierońska Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats Neuropharmacology 43 2002 181 187 (Pubitemid 35247606)
30. L. Pomierny-Chamioło, E. Poleszak, A. Pilc, and G. Nowak NMDA but not AMPA glutamatergic receptors are involved in the antidepressant-like activity of MTEP during the forced swim test in mice Pharmacol. Rep. 62 2010 1186 1190
31. E. Tatarczyńska, A. Kłodzińska, E. Chojnacka-Wójcik, A. Pałucha, F. Gasparini, R. Kuhn, and A. Pilc Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist Br. J. Pharmacol. 132 2001 1423 1430 (Pubitemid 32281030)
32. H.U. Wittchen, F. Jacobi, J. Rehm, A. Gustavsson, M. Svensson, B. Jönsson, J. Olesen, C. Allgulander, J. Alonso, C. Faravelli, L. Fratiglioni, P. Jennum, R. Lieb, A. Maercker, J. van Os, M. Preisig, L. Salvador-Carulla, R. Simon, and H.C. Steinhausen The size and burden of mental disorders and other disorders of the brain in Europe 2010 Eur. Neuropsychopharmacol. 21 2011 655 679
33. C.A. Zarate Jr., J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, D.A. Luckenbaugh, D.S. Charney, and H.K. Manji A randomized trial of an N-methyl-D aspartate antagonist in treatment-resistant major depression Arch. Gen. Psychiatry 63 2006 856 864 (Pubitemid 44188478)